香港严重过敏反应联盟关于急诊环境下处方肾上腺素自动注射器的共识声明
该共识由香港严重过敏反应联盟采用德尔菲法制定,共识定义为同意率≥80%,共形成7条共识声明,过敏科与急诊科医师间总体同意度良好。共识建议肾上腺素自动注射器作为一线治疗并为所有有严重过敏反应风险的患者处方,应在急诊离院前处方并立即转诊过敏中心。处方决策应基于既往反应严重程度(包括客观呼吸系统受累、客观心血管系统受累和多器官受累,无论严重程度)以及患者人口学特征和合并症(特别是哮喘或慢性阻塞性肺疾病史)。符合条件者应接受回避建议并处方一支自动注射器等待过敏科医师评估,同时应由医护人员演示注射技术或播放教学视频并要求患者回示。
要点
- 有严重过敏反应风险的患者应在急诊离院前处方肾上腺素自动注射器,并立即转诊过敏中心。
- 处方决策基于既往反应严重程度:客观呼吸系统受累、客观心血管系统受累和多器官受累(无论严重程度)。
- 患者人口学特征和合并症(特别是哮喘或慢性阻塞性肺疾病史)也应纳入处方决策考虑。
- 符合条件者应接受回避建议并处方一支自动注射器,等待过敏科医师评估。
- 应由医护人员演示注射技术或播放教学视频,并要求患者回示;应告知患者长期处方需求由过敏科医师评估。
适用人群与场景
- 有严重过敏反应风险的患者,在急诊科就诊后离院前评估。
诊断标准与关键阈值
- 处方肾上腺素自动注射器的决策应基于既往反应严重程度,包括客观呼吸系统受累、客观心血管系统受累和多器官受累(无论严重程度)。
- 患者人口学特征和合并症,特别是哮喘或慢性阻塞性肺疾病史,也应考虑。
处置流程与药物剂量
- 肾上腺素自动注射器应作为一线治疗,并为所有有严重过敏反应风险的患者处方。
- 应在急诊离院前处方肾上腺素自动注射器,并立即转诊过敏中心。
- 符合条件者应接受回避建议并处方一支肾上腺素自动注射器,等待过敏科医师评估。
- 应由医护人员演示注射技术或播放教学视频,并要求患者回示。
- 应告知患者长期处方需求由过敏科医师评估。
研究设计与关键结果
- 香港严重过敏反应联盟采用德尔菲法制定共识声明,共识定义为同意率≥80%。
- 共7条声明达到共识标准,过敏科与急诊科医师间总体同意度良好。
证据类型、等级与局限
- 证据类型:共识声明(德尔菲法)。
- 共识阈值:同意率≥80%。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊科医师应为有严重过敏反应风险的患者在离院前处方肾上腺素自动注射器并立即转诊过敏中心。
- 处方决策应基于既往反应严重程度(客观呼吸系统受累、客观心血管系统受累、多器官受累)及合并症(特别是哮喘或慢性阻塞性肺疾病史)。
- 应向患者提供回避建议、处方一支自动注射器、演示注射技术并要求回示,告知长期需求由过敏科医师评估。
指南或共识出处
- 香港严重过敏反应联盟共识声明(Hong Kong Anaphylaxis Consortium Consensus Statements)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Adrenaline autoinjectors (AAInj) facilitates early administration of adrenaline and remains the first-line treatment for anaphylaxis. However, only a minority of anaphylaxis survivors in Hong Kong are prescribed AAInj and formal guidance do not exist. International anaphylaxis guidelines have been largely based on Western studies, which may not be as relevant for non-Western populations.
OBJECTIVE: To formulate a set of consensus statements on the prescription of AAInj in Hong Kong.
METHODS: Consensus statements were formulated by the Hong Kong Anaphylaxis Consortium by the Delphi method. Agreement was defined as greater than or equal to 80% consensus. Subgroup analysis was performed to investigate differences between allergy and emergency medicine physicians.
RESULTS: A total of 7 statements met criteria for consensus with good overall agreement between allergy and emergency medicine physicians. AAInj should be used as first-line treatment and prescribed for all patients at risk of anaphylaxis. This should be prescribed prior to discharge from the Accident and Emergency Department together with an immediate referral to an allergy center. The decision for prescribing AAInj should be based on the severity of previous reactions; including objective signs of respiratory involvement, objective signs of cardiovascular involvement and multiorgan involvement (regardless of severity). Patient demographics and comorbidities, specifically history of asthma or chronic obstructive pulmonary disease, should also be considered. Patients deemed eligible for AAInj should be offered avoidance advice and prescribed one AAInj while awaiting review by allergists. AAInj technique should be demonstrated by a healthcare professional or instruction video, and a return demonstration by the patient is required. The patient should also be counseled that the decision on the continued need of AAInj prescription in the long-term should be reviewed by an allergist.
CONCLUSION: Consensus statements support the prescription of AAInj by front-line physicians with subsequent allergist review when treating patients at risk of anaphylaxis in Hong Kong.
参考来源
- Li PH, Chua GT, Leung ASY, et al. Hong Kong Anaphylaxis Consortium Consensus Statements on prescription of adrenaline autoinjectors in the acute care setting. Asia Pac Allergy. 2021. PMID: 33604271. doi:10.5415/apallergy.2021.11.e1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。